论文部分内容阅读
目的观察晚期癌症患者服用甲孕酮后改善化疗所致毒副反应,及止痛和促进蛋白同化的作用。方法66例晚期癌症患者随机分为化疗+甲孕酮组及单用化疗组。结果并用甲孕酮组34例患者82·4%(28/34)进食量增加,78·2%(26/34)体重增加,平均血浆白蛋白增加(1·3±2·7)g/L,血红蛋白增加(3·1±1·6)g/L,35·3%(12/34)ECOG改善,88·8%患者疼痛减轻,化疗的毒副反应按WHO化疗药物急性毒性分级标准,Ⅱ度以上血红蛋白下降发生率12·5%,白细胞下降发生率37·5%,胃肠道反应18·8%,平均恢复天数分别为(4·6±3·3)d、(6·6±3·7)d、(2·4±1·3)d,以上各项指标与单用化疗组相比差异有显著意义。结论甲孕酮用于晚期癌症的治疗,可以改善化疗期间癌症患者的生活质量。
Objective To observe the effect of chemotherapy-induced side effects and analgesia and protein assimilation after taking medroxyprogesterone in patients with advanced cancer. Methods Sixty-six patients with advanced cancer were randomly divided into chemotherapy plus medroxyprogesterone acetate group and chemotherapy alone group. Results In the 34 patients with medroxyprogesterone acetate, 82.4% (28/34) increased their food intake, 78.2% (26/34) gained weight, and mean plasma albumin increased by (1.3 ± 2.7) g / L, hemoglobin (3.1 ± 1.6) g / L, 35.3% (12/34) ECOG, and 88.8% of patients had pain relief. The toxicity of chemotherapy was determined according to the WHO Acute Toxicity Scale of Chemotherapy , The incidence of hemoglobin decrease 12.5%, the incidence of leukopenia 37.5% and the gastrointestinal reaction 18.8%, the average recovery days were (4.6 ± 3.3) d 6 ± 3 · 7) d, (2 · 4 ± 1 · 3) d, the above indexes were significantly different from the chemotherapy alone group. Conclusion Medroxyprogesterone acetate can be used in the treatment of advanced cancer and can improve the quality of life of cancer patients during chemotherapy.